Press release titled 'Windlas Biotech Limited Reports its Q1 FY27 Financial Results'

Windlas Biotech Limited Reg. Off.: 40/1, Mohabewala Industrial Area Dehradun, Uttarakhand 248 110, India Tel.:+91-135-6608000-30, Fax:+91-135-6608199 Corp. Off.: 705-706, Vatika Professional Point, Sector-66, Golf Course Ext. Road, Gurgaon, Haryana 122 001, India Tel.:+91-124-2821030 CIN-L74899UR2001PLC033407 August 10, 2026 To To Listing / Compliance Department Listing / Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Mumbai – 400 001 Bandra Kurla Complex Bandra (E), Mumbai – 400 051 BSE CODE: 543329 NSE SYMBOL: WINDLAS Dear Sir/ Madam. Sub: Press Release Please find attached herewith press release titled “Windlas Biotech Limited Reports its Q1 FY27 Financial Results”. Kindly take the same on record. Thanking you, Yours faithfully, For Windlas Biotech Limited Ananta Narayan Panda Company Secretary & Compliance Officer Encl: as above www.windlas.com Press Release Windlas Biotech Limited Reports its Q1 FY27 Financial Results  14th consecu(cid:415)ve quarter of record Revenue, Rs 248 crores (Q1FY27)  Adjusted EBITDA recorded at Rs 34 crores; growth of 26% YoY (Q1FY27)  Adjusted PAT growth of 37% YoY to Rs 25 crores (Q1FY27)  Successfully completed Rs 47 crore share buyback without Promotor’s par(cid:415)cipa(cid:415)on  Dividend paid Rs 13 crores (Rs 6.3 per share) for FY26  Reported EPS of Rs 8.46 Monday, 10th August 2026, Gurugram: Windlas Biotech Limited, one of the leading players in the domes(cid:415)c pharmaceu(cid:415)cal formula(cid:415)ons contract development and manufacturing organiza(cid:415)on (“CDMO”) industry in India, reported its unaudited financials for the quarter ended June 30, 2026. Consolidated Highlights: Q1FY27 Highlights:  Revenue from opera(cid:415)ons stood at Rs 248 crores as against Rs 210 crores, a growth of 18% YoY  Adjusted EBITDA stood at Rs 34 crores as against Rs 27 crores, a growth of 26% YoY. Adjusted EBITDA Margin came in at 13.6%  Adjusted PAT stood at Rs 25 crores as against Rs 18 crores, a growth of 37% YoY. PAT Margin came in at 10% Note: 1) Adjusted EBITDA & Margin and PAT & Margin are excluding the impact of Non-cash ESOP expenses of Rs 7.16 Cr. 2) Reported EBITDA stood at Rs 27 crores. Reported PAT stood at Rs 18 crores. Ver(cid:415)cal Performance Update: Par(cid:415)culars (In Rs. Crores) Q1FY27 Q1FY26 Y-o-Y Generic Formula(cid:415)ons CDMO 207 160 29% Trade Generics & Ins(cid:415)tu(cid:415)onal 30 44 -32% Exports 11 6 79% Generic Formula(cid:415)ons CDMO Ver(cid:415)cal Highlights  Q1FY26 revenue for the CDMO ver(cid:415)cal stood at Rs 207 crores, up 29% YoY.  CDMO ver(cid:415)cal contributed approximately 84% for Q1FY27 to the consolidated revenue. Trade Generics & Ins(cid:415)tu(cid:415)onal Ver(cid:415)cal Highlights  Q1FY27 revenue for the Trade Generics & Ins(cid:415)tu(cid:415)onal ver(cid:415)cal stood at Rs 30 crores, down -32% YoY.  Trade Generics ver(cid:415)cal contributed approximately 12% for Q1FY27 to the consolidated revenue. Exports Ver(cid:415)cal Highlights  Q1FY27 revenue for the Exports ver(cid:415)cal stood at Rs 11 crores, up 79% YoY.  Exports ver(cid:415)cal contributed approximately 4% for Q1FY27 to the consolidated revenue. Commen(cid:415)ng on the results Mr. Hitesh Windlass, Managing Director – Windlas Biotech said, “The Indian Pharmaceutical Market (IPM) witnessed a volume growth of 3.4% in Q1 FY27, reflecting a steady yet measured industry environment. Against this backdrop, Windlas Biotech continued its growth trajectory, delivering its highest-ever quarterly revenue of ₹248 crore, representing 18% YoY growth. This performance underscores the strength and resilience of our diversified business model, our operational excellence, and the trust our customers place in us. We are on track for the commercialization of Plant-6 in H1 FY27, which will further strengthen our manufacturing capacity and enable us to support future growth opportunities. Our Injectables and Plant-2 Extension facilities continue to drive scalable growth, highlighting the effectiveness of our strategic investments. We remain focused on creating sustainable value through disciplined execution, talent development, client diversification, capability enhancement, and expansion across dosage forms. I would like to thank our customers, partners and employees, shareholders for their continued trust and support.” Adding further, Ms. Komal Gupta, CEO & CFO - Windlas Biotech said, “We have started FY27 with a posi(cid:415)ve note by extending our record revenue streak to 14 consecu(cid:415)ve quarters with 18% YoY growth to Rs 248 crore. Consistent with our focus on long-term shareholders value crea(cid:415)on, in Q1 FY27 the company also completed ₹47 crore buyback in which promoters did not par(cid:415)cipate and declara(cid:415)on of FY26 dividend ₹13 crore (₹6.30 per equity share). Excluding the impact of ESOP expenses (₹7.2 Crore) which are non-cash in nature, our EBITDA grew 26% YoY to ₹34 crore, PBT and PAT grew 27% and 37% YoY to ₹30 crore and ₹25 crore respec(cid:415)vely, reflec(cid:415)ng our con(cid:415)nued focus on improving opera(cid:415)onal leverage. If we take into account Non-cash ESOP expenditure (₹7.2 crore), the company reported EBITDA ₹27 crore, PBT ₹23 crore and PAT ₹18 crore. For Q1 FY27 Earnings Per Share (EPS) has improved to ₹ 8.46. Our Generic Formula(cid:415)ons CDMO ver(cid:415)cal delivered 29% YoY revenue growth to ₹207 crore, driven by customer expansion, deeper customer engagement, and new product launches. The Trade Generics & Ins(cid:415)tu(cid:415)onal ver(cid:415)cal reported revenue of ₹30 crore, following the discon(cid:415)nua(cid:415)on of codeine-based products. As we expand the por(cid:414)olio with new launches and replacements, we expect to progressively bridge the gap. Our Exports ver(cid:415)cal recorded 79% YoY growth to ₹11 crore. We remain focused on long-term company level performance rather than quarterly and ver(cid:415)cal wise fluctua(cid:415)ons and are confident in the underlying growth opportunity in all three ver(cid:415)cals. Looking ahead, our priori(cid:415)es remain focused on strengthening strategic partnerships, expanding our offerings, achieving opera(cid:415)onal excellence, accelera(cid:415)ng por(cid:414)olio development, and driving disciplined execu(cid:415)on. Supported by a modernized manufacturing base, a talented workforce, and a clear strategic direc(cid:415)on, we are well posi(cid:415)oned to capitalize on the opportuni(cid:415)es across all three business ver(cid:415)cals.” About Windlas Biotech Limited The company (Windlas) is amongst the top five players in the domes(cid:415)c pharmaceu(cid:415)cal formula(cid:415)ons contract development and manufacturing organiza(cid:415)on (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceu(cid:415)cal dosage forms and significant experience in providing specialized capabili(cid:415)es, including, high potency, controlled substances and low solubility, the Company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Prac(cid:415)ces (“GMP”) with a focus on improved safety, efficacy and cost. Safe Harbor Statements in this document rela(cid:415)ng to future status, events, or circumstances, including but not limited to statements about plans and objec(cid:415)ves, the progress and results of research and development, poten(cid:415)al project characteris(cid:415)cs, project poten(cid:415)al and target dates for project- related issues are forward-looking statements based on es(cid:415)mates and the an(cid:415)cipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks a [Showing first 8,000 characters — download PDF for full document]